Form 4: AN2 Therapeutics Director Patricia Martin Acquires Shares as Compensation

AN2 Therapeutics Director Patricia A. Martin received 3,750 shares of common stock on July 10, 2025, as non-cash compensation, increasing her total beneficial ownership to 9,981 shares.

Summary

• Patricia A. Martin, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 3,750 shares of common stock.
• The transaction occurred on July 10, 2025.
• These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy.
• All acquired shares vested immediately.
• Following this transaction, Patricia A. Martin beneficially owns 9,981 shares of AN2 Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their stake, aligning interests with shareholders, even if it's through compensation. It's a routine transaction, not indicative of major news, but generally viewed favorably.

Positives

• Director Patricia A. Martin increased her beneficial ownership in AN2 Therapeutics by acquiring 3,750 shares.
• The shares were issued as compensation, aligning director interests with shareholders.
• All acquired shares vested immediately, indicating immediate full ownership.

Negatives

• No specific negatives are indicated in this Form 4 filing, as it primarily reports a routine compensation-related stock acquisition by a director.

Risks

• No specific risks are detailed in this Form 4 filing, which is a transaction report.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• No direct management comments or quotes are included in this Form 4 filing, which is a regulatory transaction report.

Industry Context

This transaction reflects a common practice in the biotechnology and pharmaceutical industries where non-employee directors receive equity compensation, aligning their interests with long-term shareholder value. It is a standard mechanism for director remuneration.

Comparison to Industry Standards

• This Form 4 reports a routine director compensation event, which is a standard practice across publicly traded companies, particularly in the biotech sector. The specific number of shares or value of compensation would typically be benchmarked against peer companies of similar market capitalization and stage of development, but this document does not provide enough detail for such a comparison.

Related Party Transactions

• Acquisition of 3,750 shares of common stock by Patricia A. Martin, a Director, as compensation in lieu of cash under the issuer's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director through compensation aligns the director's financial interests with those of the shareholders, potentially fostering a greater focus on long-term company performance.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Trading, Director Compensation, Stock Acquisition, Patricia A. Martin, Equity Compensation